Various plasmatic cytokines and inflammatory markers in patients with AMN were reduced after multi-antioxidant combination therapy, among which inflammatory markers, such as monocyte chemoattractant protein-1 (MCP1) and 15-hydroxyeicosatetraenoic acid (15-HETE), were significantly downregulated to become the promising predictors of response to treatment (8). This evidence concerns the gene CCL2 and adrenomyeloneuropathy.